nodes	percent_of_prediction	percent_of_DWPC	metapath
Melphalan—Alkylating Activity—Dacarbazine—muscle cancer	0.516	1	CiPCiCtD
Melphalan—hematologic cancer—muscle cancer	0.239	0.65	CtDrD
Melphalan—peripheral nervous system neoplasm—muscle cancer	0.129	0.35	CtDrD
Melphalan—SLC22A3—Vincristine—muscle cancer	0.0692	1	CbGbCtD
Melphalan—SLC7A5—smooth muscle tissue—muscle cancer	0.00031	0.117	CbGeAlD
Melphalan—Hyperuricaemia—Vincristine—muscle cancer	0.000272	0.00628	CcSEcCtD
Melphalan—SLC7A5—cardiac atrium—muscle cancer	0.000267	0.101	CbGeAlD
Melphalan—Blood uric acid increased—Vincristine—muscle cancer	0.000257	0.00593	CcSEcCtD
Melphalan—Mouth ulceration—Dactinomycin—muscle cancer	0.000256	0.0059	CcSEcCtD
Melphalan—Tingling sensation—Etoposide—muscle cancer	0.000255	0.00587	CcSEcCtD
Melphalan—Interstitial pneumonia—Methotrexate—muscle cancer	0.000254	0.00585	CcSEcCtD
Melphalan—SLC22A3—embryo—muscle cancer	0.000245	0.0925	CbGeAlD
Melphalan—Neuropathy—Vincristine—muscle cancer	0.000237	0.00547	CcSEcCtD
Melphalan—Extravasation—Etoposide—muscle cancer	0.000235	0.00541	CcSEcCtD
Melphalan—SLC7A5—tendon—muscle cancer	0.000233	0.0881	CbGeAlD
Melphalan—Mouth ulceration—Vincristine—muscle cancer	0.000228	0.00527	CcSEcCtD
Melphalan—Myelosuppression—Doxorubicin—muscle cancer	0.000226	0.00522	CcSEcCtD
Melphalan—SLC7A5—bone marrow—muscle cancer	0.000226	0.0853	CbGeAlD
Melphalan—Hyperuricaemia—Etoposide—muscle cancer	0.000221	0.00509	CcSEcCtD
Melphalan—Ulcer—Etoposide—muscle cancer	0.000216	0.00499	CcSEcCtD
Melphalan—SLC7A5—vagina—muscle cancer	0.000216	0.0817	CbGeAlD
Melphalan—Blood uric acid increased—Etoposide—muscle cancer	0.000208	0.00481	CcSEcCtD
Melphalan—Febrile neutropenia—Methotrexate—muscle cancer	0.000204	0.0047	CcSEcCtD
Melphalan—SLC7A5—head—muscle cancer	0.0002	0.0755	CbGeAlD
Melphalan—Skin exfoliation—Etoposide—muscle cancer	0.000195	0.00451	CcSEcCtD
Melphalan—SLC7A5—testis—muscle cancer	0.000193	0.0729	CbGeAlD
Melphalan—SLC22A3—smooth muscle tissue—muscle cancer	0.000193	0.0728	CbGeAlD
Melphalan—Neuropathy—Etoposide—muscle cancer	0.000192	0.00443	CcSEcCtD
Melphalan—Local reaction—Doxorubicin—muscle cancer	0.000192	0.00442	CcSEcCtD
Melphalan—Liver function test abnormal—Dactinomycin—muscle cancer	0.000189	0.00437	CcSEcCtD
Melphalan—SLC22A3—renal system—muscle cancer	0.000185	0.07	CbGeAlD
Melphalan—Mouth ulceration—Etoposide—muscle cancer	0.000185	0.00427	CcSEcCtD
Melphalan—Hyponatraemia—Vincristine—muscle cancer	0.000184	0.00425	CcSEcCtD
Melphalan—Bone marrow depression—Methotrexate—muscle cancer	0.000182	0.00419	CcSEcCtD
Melphalan—Liver disorder—Methotrexate—muscle cancer	0.00018	0.00415	CcSEcCtD
Melphalan—Febrile neutropenia—Doxorubicin—muscle cancer	0.000176	0.00407	CcSEcCtD
Melphalan—Transaminases increased—Doxorubicin—muscle cancer	0.000174	0.00402	CcSEcCtD
Melphalan—Cardiac arrest—Vincristine—muscle cancer	0.000174	0.00402	CcSEcCtD
Melphalan—Interstitial lung disease—Methotrexate—muscle cancer	0.000173	0.00399	CcSEcCtD
Melphalan—Pancytopenia—Dactinomycin—muscle cancer	0.000168	0.00389	CcSEcCtD
Melphalan—Neutropenia—Dactinomycin—muscle cancer	0.000166	0.00383	CcSEcCtD
Melphalan—Skin ulcer—Methotrexate—muscle cancer	0.000157	0.00363	CcSEcCtD
Melphalan—Bone marrow depression—Doxorubicin—muscle cancer	0.000157	0.00363	CcSEcCtD
Melphalan—Stomatitis—Dactinomycin—muscle cancer	0.000154	0.00356	CcSEcCtD
Melphalan—Pancytopenia—Vincristine—muscle cancer	0.00015	0.00347	CcSEcCtD
Melphalan—Neutropenia—Vincristine—muscle cancer	0.000148	0.00342	CcSEcCtD
Melphalan—Dermatitis atopic—Doxorubicin—muscle cancer	0.000143	0.00331	CcSEcCtD
Melphalan—Hepatitis—Dactinomycin—muscle cancer	0.000142	0.00328	CcSEcCtD
Melphalan—Cardiac arrest—Etoposide—muscle cancer	0.000141	0.00326	CcSEcCtD
Melphalan—Extravasation—Methotrexate—muscle cancer	0.00014	0.00324	CcSEcCtD
Melphalan—Neuropathy peripheral—Vincristine—muscle cancer	0.000138	0.0032	CcSEcCtD
Melphalan—Stomatitis—Vincristine—muscle cancer	0.000138	0.00318	CcSEcCtD
Melphalan—Skin ulcer—Doxorubicin—muscle cancer	0.000136	0.00314	CcSEcCtD
Melphalan—Feeling hot—Doxorubicin—muscle cancer	0.000135	0.00312	CcSEcCtD
Melphalan—SLC22A3—vagina—muscle cancer	0.000134	0.0507	CbGeAlD
Melphalan—Hyperuricaemia—Methotrexate—muscle cancer	0.000132	0.00305	CcSEcCtD
Melphalan—Flushing—Dactinomycin—muscle cancer	0.000132	0.00304	CcSEcCtD
Melphalan—Ulcer—Methotrexate—muscle cancer	0.00013	0.00299	CcSEcCtD
Melphalan—Bronchospasm—Etoposide—muscle cancer	0.000126	0.00291	CcSEcCtD
Melphalan—Vasculitis—Methotrexate—muscle cancer	0.000126	0.0029	CcSEcCtD
Melphalan—Alopecia—Dactinomycin—muscle cancer	0.000125	0.00289	CcSEcCtD
Melphalan—Urinary tract disorder—Vincristine—muscle cancer	0.000125	0.00289	CcSEcCtD
Melphalan—Blood uric acid increased—Methotrexate—muscle cancer	0.000125	0.00288	CcSEcCtD
Melphalan—Connective tissue disorder—Vincristine—muscle cancer	0.000125	0.00288	CcSEcCtD
Melphalan—Urethral disorder—Vincristine—muscle cancer	0.000124	0.00287	CcSEcCtD
Melphalan—Neoplasm malignant—Doxorubicin—muscle cancer	0.000124	0.00287	CcSEcCtD
Melphalan—SLC22A3—head—muscle cancer	0.000124	0.0469	CbGeAlD
Melphalan—Pancytopenia—Etoposide—muscle cancer	0.000122	0.00281	CcSEcCtD
Melphalan—Extravasation—Doxorubicin—muscle cancer	0.000122	0.00281	CcSEcCtD
Melphalan—Amenorrhoea—Doxorubicin—muscle cancer	0.000121	0.00279	CcSEcCtD
Melphalan—Neutropenia—Etoposide—muscle cancer	0.00012	0.00277	CcSEcCtD
Melphalan—SLC22A3—testis—muscle cancer	0.00012	0.0453	CbGeAlD
Melphalan—Cystitis noninfective—Methotrexate—muscle cancer	0.00012	0.00276	CcSEcCtD
Melphalan—Cystitis—Methotrexate—muscle cancer	0.000118	0.00273	CcSEcCtD
Melphalan—Skin exfoliation—Methotrexate—muscle cancer	0.000117	0.0027	CcSEcCtD
Melphalan—Hyperuricaemia—Doxorubicin—muscle cancer	0.000114	0.00264	CcSEcCtD
Melphalan—Mediastinal disorder—Vincristine—muscle cancer	0.000114	0.00264	CcSEcCtD
Melphalan—Anaemia—Dactinomycin—muscle cancer	0.000114	0.00264	CcSEcCtD
Melphalan—Ulcer—Doxorubicin—muscle cancer	0.000112	0.00259	CcSEcCtD
Melphalan—Neuropathy peripheral—Etoposide—muscle cancer	0.000112	0.00259	CcSEcCtD
Melphalan—Alopecia—Vincristine—muscle cancer	0.000112	0.00259	CcSEcCtD
Melphalan—Stomatitis—Etoposide—muscle cancer	0.000112	0.00257	CcSEcCtD
Melphalan—Jaundice—Etoposide—muscle cancer	0.000112	0.00257	CcSEcCtD
Melphalan—Neoplasm—Methotrexate—muscle cancer	0.000111	0.00256	CcSEcCtD
Melphalan—Bladder pain—Methotrexate—muscle cancer	0.000111	0.00256	CcSEcCtD
Melphalan—Mouth ulceration—Methotrexate—muscle cancer	0.000111	0.00256	CcSEcCtD
Melphalan—Leukopenia—Dactinomycin—muscle cancer	0.000111	0.00255	CcSEcCtD
Melphalan—Hepatobiliary disease—Etoposide—muscle cancer	0.000108	0.0025	CcSEcCtD
Melphalan—Blood uric acid increased—Doxorubicin—muscle cancer	0.000108	0.00249	CcSEcCtD
Melphalan—Hepatocellular injury—Doxorubicin—muscle cancer	0.000106	0.00245	CcSEcCtD
Melphalan—Injection site reaction—Doxorubicin—muscle cancer	0.000105	0.00243	CcSEcCtD
Melphalan—Myalgia—Dactinomycin—muscle cancer	0.000105	0.00243	CcSEcCtD
Melphalan—Cystitis noninfective—Doxorubicin—muscle cancer	0.000104	0.00239	CcSEcCtD
Melphalan—Cystitis—Doxorubicin—muscle cancer	0.000102	0.00236	CcSEcCtD
Melphalan—Anaemia—Vincristine—muscle cancer	0.000102	0.00235	CcSEcCtD
Melphalan—Urinary tract disorder—Etoposide—muscle cancer	0.000101	0.00234	CcSEcCtD
Melphalan—Skin exfoliation—Doxorubicin—muscle cancer	0.000101	0.00234	CcSEcCtD
Melphalan—Oedema—Dactinomycin—muscle cancer	0.000101	0.00233	CcSEcCtD
Melphalan—Urethral disorder—Etoposide—muscle cancer	0.000101	0.00232	CcSEcCtD
Melphalan—Infection—Dactinomycin—muscle cancer	0.0001	0.00231	CcSEcCtD
Melphalan—Neuropathy—Doxorubicin—muscle cancer	9.96e-05	0.0023	CcSEcCtD
Melphalan—Leukopenia—Vincristine—muscle cancer	9.88e-05	0.00228	CcSEcCtD
Melphalan—Thrombocytopenia—Dactinomycin—muscle cancer	9.88e-05	0.00228	CcSEcCtD
Melphalan—Renal failure acute—Methotrexate—muscle cancer	9.64e-05	0.00222	CcSEcCtD
Melphalan—Anorexia—Dactinomycin—muscle cancer	9.61e-05	0.00222	CcSEcCtD
Melphalan—Neoplasm—Doxorubicin—muscle cancer	9.59e-05	0.00221	CcSEcCtD
Melphalan—Mouth ulceration—Doxorubicin—muscle cancer	9.59e-05	0.00221	CcSEcCtD
Melphalan—Bladder pain—Doxorubicin—muscle cancer	9.59e-05	0.00221	CcSEcCtD
Melphalan—Convulsion—Vincristine—muscle cancer	9.57e-05	0.00221	CcSEcCtD
Melphalan—Flushing—Etoposide—muscle cancer	9.54e-05	0.0022	CcSEcCtD
Melphalan—Myalgia—Vincristine—muscle cancer	9.4e-05	0.00217	CcSEcCtD
Melphalan—Immune system disorder—Etoposide—muscle cancer	9.28e-05	0.00214	CcSEcCtD
Melphalan—Mediastinal disorder—Etoposide—muscle cancer	9.26e-05	0.00214	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Dactinomycin—muscle cancer	9.19e-05	0.00212	CcSEcCtD
Melphalan—Alopecia—Etoposide—muscle cancer	9.08e-05	0.00209	CcSEcCtD
Melphalan—Anaphylactic shock—Vincristine—muscle cancer	9.01e-05	0.00208	CcSEcCtD
Melphalan—Oedema—Vincristine—muscle cancer	9.01e-05	0.00208	CcSEcCtD
Melphalan—Infection—Vincristine—muscle cancer	8.95e-05	0.00207	CcSEcCtD
Melphalan—Thrombocytopenia—Vincristine—muscle cancer	8.82e-05	0.00204	CcSEcCtD
Melphalan—Decreased appetite—Dactinomycin—muscle cancer	8.77e-05	0.00202	CcSEcCtD
Melphalan—Fatigue—Dactinomycin—muscle cancer	8.7e-05	0.00201	CcSEcCtD
Melphalan—Pain—Dactinomycin—muscle cancer	8.63e-05	0.00199	CcSEcCtD
Melphalan—Anorexia—Vincristine—muscle cancer	8.59e-05	0.00198	CcSEcCtD
Melphalan—Hypotension—Vincristine—muscle cancer	8.42e-05	0.00194	CcSEcCtD
Melphalan—Renal failure acute—Doxorubicin—muscle cancer	8.34e-05	0.00192	CcSEcCtD
Melphalan—Anaemia—Etoposide—muscle cancer	8.27e-05	0.00191	CcSEcCtD
Melphalan—Liver function test abnormal—Methotrexate—muscle cancer	8.21e-05	0.00189	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Vincristine—muscle cancer	8.21e-05	0.00189	CcSEcCtD
Melphalan—Paraesthesia—Vincristine—muscle cancer	8.09e-05	0.00187	CcSEcCtD
Melphalan—Leukopenia—Etoposide—muscle cancer	8.01e-05	0.00185	CcSEcCtD
Melphalan—Decreased appetite—Vincristine—muscle cancer	7.83e-05	0.00181	CcSEcCtD
Melphalan—Cough—Etoposide—muscle cancer	7.81e-05	0.0018	CcSEcCtD
Melphalan—Gastrointestinal disorder—Vincristine—muscle cancer	7.78e-05	0.00179	CcSEcCtD
Melphalan—Fatigue—Vincristine—muscle cancer	7.77e-05	0.00179	CcSEcCtD
Melphalan—Convulsion—Etoposide—muscle cancer	7.75e-05	0.00179	CcSEcCtD
Melphalan—Hyponatraemia—Doxorubicin—muscle cancer	7.73e-05	0.00178	CcSEcCtD
Melphalan—Pain—Vincristine—muscle cancer	7.71e-05	0.00178	CcSEcCtD
Melphalan—Chest pain—Etoposide—muscle cancer	7.61e-05	0.00176	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	7.56e-05	0.00174	CcSEcCtD
Melphalan—Hypersensitivity—Dactinomycin—muscle cancer	7.43e-05	0.00171	CcSEcCtD
Melphalan—Cardiac arrest—Doxorubicin—muscle cancer	7.32e-05	0.00169	CcSEcCtD
Melphalan—Pancytopenia—Methotrexate—muscle cancer	7.3e-05	0.00168	CcSEcCtD
Melphalan—Anaphylactic shock—Etoposide—muscle cancer	7.3e-05	0.00168	CcSEcCtD
Melphalan—Infection—Etoposide—muscle cancer	7.25e-05	0.00167	CcSEcCtD
Melphalan—Asthenia—Dactinomycin—muscle cancer	7.24e-05	0.00167	CcSEcCtD
Melphalan—Neutropenia—Methotrexate—muscle cancer	7.19e-05	0.00166	CcSEcCtD
Melphalan—Thrombocytopenia—Etoposide—muscle cancer	7.15e-05	0.00165	CcSEcCtD
Melphalan—Tachycardia—Etoposide—muscle cancer	7.12e-05	0.00164	CcSEcCtD
Melphalan—Liver function test abnormal—Doxorubicin—muscle cancer	7.11e-05	0.00164	CcSEcCtD
Melphalan—Skin disorder—Etoposide—muscle cancer	7.09e-05	0.00164	CcSEcCtD
Melphalan—Anorexia—Etoposide—muscle cancer	6.96e-05	0.00161	CcSEcCtD
Melphalan—Diarrhoea—Dactinomycin—muscle cancer	6.9e-05	0.00159	CcSEcCtD
Melphalan—Hypotension—Etoposide—muscle cancer	6.82e-05	0.00157	CcSEcCtD
Melphalan—Stomatitis—Methotrexate—muscle cancer	6.68e-05	0.00154	CcSEcCtD
Melphalan—Hypersensitivity—Vincristine—muscle cancer	6.64e-05	0.00153	CcSEcCtD
Melphalan—Paraesthesia—Etoposide—muscle cancer	6.55e-05	0.00151	CcSEcCtD
Melphalan—Dyspnoea—Etoposide—muscle cancer	6.51e-05	0.0015	CcSEcCtD
Melphalan—Hepatobiliary disease—Methotrexate—muscle cancer	6.48e-05	0.0015	CcSEcCtD
Melphalan—Asthenia—Vincristine—muscle cancer	6.47e-05	0.00149	CcSEcCtD
Melphalan—Vomiting—Dactinomycin—muscle cancer	6.41e-05	0.00148	CcSEcCtD
Melphalan—Rash—Dactinomycin—muscle cancer	6.36e-05	0.00147	CcSEcCtD
Melphalan—Decreased appetite—Etoposide—muscle cancer	6.35e-05	0.00146	CcSEcCtD
Melphalan—Pancytopenia—Doxorubicin—muscle cancer	6.32e-05	0.00146	CcSEcCtD
Melphalan—Gastrointestinal disorder—Etoposide—muscle cancer	6.3e-05	0.00145	CcSEcCtD
Melphalan—Fatigue—Etoposide—muscle cancer	6.29e-05	0.00145	CcSEcCtD
Melphalan—Pain—Etoposide—muscle cancer	6.24e-05	0.00144	CcSEcCtD
Melphalan—Neutropenia—Doxorubicin—muscle cancer	6.23e-05	0.00144	CcSEcCtD
Melphalan—Haemoglobin—Methotrexate—muscle cancer	6.19e-05	0.00143	CcSEcCtD
Melphalan—Diarrhoea—Vincristine—muscle cancer	6.17e-05	0.00142	CcSEcCtD
Melphalan—Hepatitis—Methotrexate—muscle cancer	6.15e-05	0.00142	CcSEcCtD
Melphalan—Haemorrhage—Methotrexate—muscle cancer	6.15e-05	0.00142	CcSEcCtD
Melphalan—Urinary tract disorder—Methotrexate—muscle cancer	6.08e-05	0.0014	CcSEcCtD
Melphalan—Urethral disorder—Methotrexate—muscle cancer	6.03e-05	0.00139	CcSEcCtD
Melphalan—Nausea—Dactinomycin—muscle cancer	5.99e-05	0.00138	CcSEcCtD
Melphalan—Neuropathy peripheral—Doxorubicin—muscle cancer	5.82e-05	0.00134	CcSEcCtD
Melphalan—Urticaria—Etoposide—muscle cancer	5.8e-05	0.00134	CcSEcCtD
Melphalan—Stomatitis—Doxorubicin—muscle cancer	5.79e-05	0.00133	CcSEcCtD
Melphalan—Jaundice—Doxorubicin—muscle cancer	5.79e-05	0.00133	CcSEcCtD
Melphalan—Vomiting—Vincristine—muscle cancer	5.73e-05	0.00132	CcSEcCtD
Melphalan—Rash—Vincristine—muscle cancer	5.68e-05	0.00131	CcSEcCtD
Melphalan—Dermatitis—Vincristine—muscle cancer	5.68e-05	0.00131	CcSEcCtD
Melphalan—Hepatobiliary disease—Doxorubicin—muscle cancer	5.61e-05	0.0013	CcSEcCtD
Melphalan—Immune system disorder—Methotrexate—muscle cancer	5.56e-05	0.00128	CcSEcCtD
Melphalan—Mediastinal disorder—Methotrexate—muscle cancer	5.55e-05	0.00128	CcSEcCtD
Melphalan—Alopecia—Methotrexate—muscle cancer	5.44e-05	0.00125	CcSEcCtD
Melphalan—Hypersensitivity—Etoposide—muscle cancer	5.38e-05	0.00124	CcSEcCtD
Melphalan—Haemoglobin—Doxorubicin—muscle cancer	5.36e-05	0.00124	CcSEcCtD
Melphalan—Nausea—Vincristine—muscle cancer	5.35e-05	0.00123	CcSEcCtD
Melphalan—Hepatitis—Doxorubicin—muscle cancer	5.33e-05	0.00123	CcSEcCtD
Melphalan—Haemorrhage—Doxorubicin—muscle cancer	5.33e-05	0.00123	CcSEcCtD
Melphalan—Urinary tract disorder—Doxorubicin—muscle cancer	5.26e-05	0.00121	CcSEcCtD
Melphalan—Asthenia—Etoposide—muscle cancer	5.24e-05	0.00121	CcSEcCtD
Melphalan—Connective tissue disorder—Doxorubicin—muscle cancer	5.24e-05	0.00121	CcSEcCtD
Melphalan—Urethral disorder—Doxorubicin—muscle cancer	5.22e-05	0.00121	CcSEcCtD
Melphalan—Pruritus—Etoposide—muscle cancer	5.16e-05	0.00119	CcSEcCtD
Melphalan—Diarrhoea—Etoposide—muscle cancer	4.99e-05	0.00115	CcSEcCtD
Melphalan—Anaemia—Methotrexate—muscle cancer	4.95e-05	0.00114	CcSEcCtD
Melphalan—Flushing—Doxorubicin—muscle cancer	4.95e-05	0.00114	CcSEcCtD
Melphalan—Immune system disorder—Doxorubicin—muscle cancer	4.81e-05	0.00111	CcSEcCtD
Melphalan—Mediastinal disorder—Doxorubicin—muscle cancer	4.8e-05	0.00111	CcSEcCtD
Melphalan—Leukopenia—Methotrexate—muscle cancer	4.8e-05	0.00111	CcSEcCtD
Melphalan—Arrhythmia—Doxorubicin—muscle cancer	4.76e-05	0.0011	CcSEcCtD
Melphalan—Alopecia—Doxorubicin—muscle cancer	4.71e-05	0.00109	CcSEcCtD
Melphalan—Cough—Methotrexate—muscle cancer	4.68e-05	0.00108	CcSEcCtD
Melphalan—Convulsion—Methotrexate—muscle cancer	4.64e-05	0.00107	CcSEcCtD
Melphalan—Vomiting—Etoposide—muscle cancer	4.64e-05	0.00107	CcSEcCtD
Melphalan—Rash—Etoposide—muscle cancer	4.6e-05	0.00106	CcSEcCtD
Melphalan—Dermatitis—Etoposide—muscle cancer	4.6e-05	0.00106	CcSEcCtD
Melphalan—Myalgia—Methotrexate—muscle cancer	4.56e-05	0.00105	CcSEcCtD
Melphalan—Chest pain—Methotrexate—muscle cancer	4.56e-05	0.00105	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	4.53e-05	0.00105	CcSEcCtD
Melphalan—Anaphylactic shock—Methotrexate—muscle cancer	4.37e-05	0.00101	CcSEcCtD
Melphalan—Infection—Methotrexate—muscle cancer	4.34e-05	0.001	CcSEcCtD
Melphalan—Nausea—Etoposide—muscle cancer	4.34e-05	0.001	CcSEcCtD
Melphalan—Anaemia—Doxorubicin—muscle cancer	4.29e-05	0.000989	CcSEcCtD
Melphalan—Thrombocytopenia—Methotrexate—muscle cancer	4.28e-05	0.000988	CcSEcCtD
Melphalan—Skin disorder—Methotrexate—muscle cancer	4.25e-05	0.00098	CcSEcCtD
Melphalan—Anorexia—Methotrexate—muscle cancer	4.17e-05	0.000962	CcSEcCtD
Melphalan—Leukopenia—Doxorubicin—muscle cancer	4.15e-05	0.000958	CcSEcCtD
Melphalan—Hypotension—Methotrexate—muscle cancer	4.09e-05	0.000943	CcSEcCtD
Melphalan—Cough—Doxorubicin—muscle cancer	4.05e-05	0.000934	CcSEcCtD
Melphalan—Convulsion—Doxorubicin—muscle cancer	4.02e-05	0.000927	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Methotrexate—muscle cancer	3.98e-05	0.000919	CcSEcCtD
Melphalan—Chest pain—Doxorubicin—muscle cancer	3.95e-05	0.000911	CcSEcCtD
Melphalan—Myalgia—Doxorubicin—muscle cancer	3.95e-05	0.000911	CcSEcCtD
Melphalan—Paraesthesia—Methotrexate—muscle cancer	3.93e-05	0.000906	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	3.92e-05	0.000905	CcSEcCtD
Melphalan—Dyspnoea—Methotrexate—muscle cancer	3.9e-05	0.000899	CcSEcCtD
Melphalan—Dyspepsia—Methotrexate—muscle cancer	3.85e-05	0.000888	CcSEcCtD
Melphalan—Decreased appetite—Methotrexate—muscle cancer	3.8e-05	0.000877	CcSEcCtD
Melphalan—Anaphylactic shock—Doxorubicin—muscle cancer	3.79e-05	0.000873	CcSEcCtD
Melphalan—Oedema—Doxorubicin—muscle cancer	3.79e-05	0.000873	CcSEcCtD
Melphalan—Gastrointestinal disorder—Methotrexate—muscle cancer	3.77e-05	0.000871	CcSEcCtD
Melphalan—Fatigue—Methotrexate—muscle cancer	3.77e-05	0.00087	CcSEcCtD
Melphalan—Infection—Doxorubicin—muscle cancer	3.76e-05	0.000868	CcSEcCtD
Melphalan—Pain—Methotrexate—muscle cancer	3.74e-05	0.000863	CcSEcCtD
Melphalan—Thrombocytopenia—Doxorubicin—muscle cancer	3.71e-05	0.000855	CcSEcCtD
Melphalan—Tachycardia—Doxorubicin—muscle cancer	3.7e-05	0.000853	CcSEcCtD
Melphalan—Skin disorder—Doxorubicin—muscle cancer	3.68e-05	0.000848	CcSEcCtD
Melphalan—Anorexia—Doxorubicin—muscle cancer	3.61e-05	0.000833	CcSEcCtD
Melphalan—Hypotension—Doxorubicin—muscle cancer	3.54e-05	0.000816	CcSEcCtD
Melphalan—Urticaria—Methotrexate—muscle cancer	3.47e-05	0.000801	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Doxorubicin—muscle cancer	3.45e-05	0.000796	CcSEcCtD
Melphalan—Paraesthesia—Doxorubicin—muscle cancer	3.4e-05	0.000784	CcSEcCtD
Melphalan—Dyspnoea—Doxorubicin—muscle cancer	3.38e-05	0.000779	CcSEcCtD
Melphalan—Dyspepsia—Doxorubicin—muscle cancer	3.33e-05	0.000769	CcSEcCtD
Melphalan—Decreased appetite—Doxorubicin—muscle cancer	3.29e-05	0.000759	CcSEcCtD
Melphalan—Gastrointestinal disorder—Doxorubicin—muscle cancer	3.27e-05	0.000754	CcSEcCtD
Melphalan—Fatigue—Doxorubicin—muscle cancer	3.26e-05	0.000753	CcSEcCtD
Melphalan—Pain—Doxorubicin—muscle cancer	3.24e-05	0.000747	CcSEcCtD
Melphalan—Hypersensitivity—Methotrexate—muscle cancer	3.22e-05	0.000743	CcSEcCtD
Melphalan—Asthenia—Methotrexate—muscle cancer	3.14e-05	0.000724	CcSEcCtD
Melphalan—Pruritus—Methotrexate—muscle cancer	3.09e-05	0.000714	CcSEcCtD
Melphalan—Urticaria—Doxorubicin—muscle cancer	3.01e-05	0.000694	CcSEcCtD
Melphalan—Diarrhoea—Methotrexate—muscle cancer	2.99e-05	0.00069	CcSEcCtD
Melphalan—Hypersensitivity—Doxorubicin—muscle cancer	2.79e-05	0.000644	CcSEcCtD
Melphalan—Vomiting—Methotrexate—muscle cancer	2.78e-05	0.000641	CcSEcCtD
Melphalan—Rash—Methotrexate—muscle cancer	2.76e-05	0.000636	CcSEcCtD
Melphalan—Dermatitis—Methotrexate—muscle cancer	2.75e-05	0.000635	CcSEcCtD
Melphalan—Asthenia—Doxorubicin—muscle cancer	2.72e-05	0.000627	CcSEcCtD
Melphalan—Pruritus—Doxorubicin—muscle cancer	2.68e-05	0.000618	CcSEcCtD
Melphalan—Nausea—Methotrexate—muscle cancer	2.6e-05	0.000599	CcSEcCtD
Melphalan—Diarrhoea—Doxorubicin—muscle cancer	2.59e-05	0.000598	CcSEcCtD
Melphalan—Vomiting—Doxorubicin—muscle cancer	2.41e-05	0.000555	CcSEcCtD
Melphalan—Rash—Doxorubicin—muscle cancer	2.39e-05	0.000551	CcSEcCtD
Melphalan—Dermatitis—Doxorubicin—muscle cancer	2.39e-05	0.00055	CcSEcCtD
Melphalan—Nausea—Doxorubicin—muscle cancer	2.25e-05	0.000519	CcSEcCtD
